Scholar Rock's Isemblyd Wins First Muscle-Targeted SMA Approval — at $310,000 With a Fracture Warning

STRATEGIC NEWS WATCH — September 14, 2026

The FDA approved the first muscle-targeted therapy for spinal muscular atrophy at a $310,000 list price with a surprise bone-fracture warning; meanwhile, AstraZeneca’s Etcamah missed the SERENA-4 trial that would have broadened it, confining the drug to the narrow indication it won just ten days earlier.

Today’s top developments:

The FDA granted standard approval to Scholar Rock’s Isemblyd (apitegromab) for spinal muscular atrophy in patients aged two and over on September 11 — the first myostatin inhibitor to treat SMA at the muscle rather than the SMN axis, priced at $310,000 a year as an add-on to existing therapy and carrying an unexpected bone-fracture warning (BioPharma Dive)
AstraZeneca’s Etcamah (camizestrant) missed on progression-free survival in the all-comer SERENA-4 trial, confining the oral SERD to the ESR1-mutated switch population behind its September 4 accelerated approval and undercutting a roughly $5 billion first-line ambition (Pharmaphorum)
Roche and MediLink’s B7-H3 antibody-drug conjugate tam-peli extended median overall survival to 13.3 months against topotecan’s 9.4 in relapsed small cell lung cancer, but trailed GSK-Hansoh’s 18.5 months across separate trials — competing instead on a grade 3 interstitial lung disease rate of 0.9% versus rivals’ 3.9% and 4.4% (Fierce Biotech)
FDA and industry closed negotiations on the next PDUFA cycle ahead of a September 16 public meeting, floating a 50% application-fee reduction for drugs anchored to a US Phase 1 trial started after October 1, 2027, with the HHS secretary due to submit the plan to Congress by January 15, 2027 (PharmaVoice)
Novo Nordisk said it will do business as “Novo” under new chief executive Mike Doustdar and a culture programme called “The Novo Way” — a narrative reset that leaves untouched the late-stage pipeline gap, a discontinued ziltivekimab and disappointing CagriSema data, ahead of an early-2030s semaglutide patent cliff (Pharmaphorum)

What to Watch

Isemblyd’s payer reception — A $310,000-a-year add-on stacked on top of Spinraza, Zolgensma or Evrysdi, carrying a fracture warning in a population with existing skeletal fragility. The $2 billion peak forecast will be won or lost in coverage policy and prior-authorisation criteria, not prescriber enthusiasm.
What AstraZeneca does with CAMBRIA — SERENA-4 leaves camizestrant resting on the ESR1-selected switch setting. Watch the CAMBRIA-1 and CAMBRIA-2 readouts the company has now named as the broader opportunity, and whether the $5 billion ambition is formally revised.
Roche’s global Phase 3 start date — Chief medical officer Levi Garraway says “quickly,” but no date is set. A 13.3-versus-18.5-month overall-survival gap only becomes answerable in a trial built around the interstitial-lung-disease advantage that is tam-peli’s real asset.
The September 16 PDUFA meeting — With negotiations closed, the public meeting is the first look at agreed language. The US-anchored Phase 1 fee reduction is the provision with teeth; the January 15, 2027 submission deadline is the next hard date.
Novo’s late-stage pipeline, not its name — Ziltivekimab is largely gone and CagriSema’s follow-up disappointed. What Novo moves into Phase 3 over the coming quarters, not “The Novo Way,” is what addresses an early-2030s semaglutide cliff.

This brief highlights the edition’s top stories. Read the full September 14, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.

Related Stories

FDA Oncology Chief Sets Out His Agenda — and Narrows the Etcamah Precedent

Bayer’s Hyrnuo Wins Accelerated Frontline Approval in HER2-Mutant NSCLC, Seven Months Behind Boehringer

FDA Names Permanent CDER and CBER Directors While the Commissioner’s Post Awaits Confirmation